China's first rare earth nano fluorescence probe reagent for detection of COVID-19, developed and produced by Xiamen Amonmed Biotechnology Co., Ltd., has recently obtained the class III medical device registration certificate issued by the National Medical Products Administration. This product can realize the ultra-sensitive detection of SARS-CoV-2 antibody titer with the whole detection process completed in 10 minutes. It can be used as a powerful supplement to nucleic acid screening for COVID-19 prevention and control and an important tool for COVID-19 immunity evaluation. It is reported that Xiamen Amonmed Biotechnology Co., Ltd. currently has a number of authorized patents in the field of rare earth biomedicine, and has successfully developed a series of rare earth nano fluorescence immune in vitro diagnosis products with independent intellectual property rights. The reagent product developed this time has been certified by EU CE, Russia GOST, Brazil ANVISA and other countries, and contracts for supplies have been successively signed with overseas customers.
